FDA Inspection 1265022 — Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
The FDA completed an inspection of Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. on March 7, 2025 in Hangzhou. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- March 7, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Hangzhou (China)